COVID-19 Tests Boost Roche’s Q1 Sales, Reaffirms FY22 Outlook
Roche Holdings AG’s (OTC:RHHBY) Q1 FY22 sales reached CHF 16.44 billion, +10% Y/Y to (11% at constant exchange rates) on…
Barron’s Latest Picks And Pans: Meta, Netflix, Roku, Bed Bath & Beyond And This Major Wireless Carrier
Benzinga reviews this weekend's top stories on Barron's, for additional information on the latest market news, Benzinga Pro offers a 24/7 news feed, live chat and charting software.
Analysts Think Intuitive Surgical Painted ‘Cautious Picture’ For Procedure Guidance
Wells Fargo writes that despite the beat in Q1, Intuitive Surgical Inc (NASDAQ:ISRG) sounded cautious on U.S. capital placements, given rising interest…
HCA Healthcare’s Softer Guidance Pulls Hospital Peers Down
Earlier today HCA Healthcare Inc (NYSE: HCA) reported Q1 earnings and cut FY22 guidance.
The revised outlook is based on current expectations regarding the impact of the COVID-19 pandemic and related government legislation, labor cost, and inflation.
Why Are HCA Healthcare Shares Trading Lower Today
HCA Healthcare Inc (NYSE:HCA) has posted Q1 FY22 revenues of $14.94 billion, compared to $13.98 billion a year ago and beating…
Intuitive Surgical Q1 Slightly Ahead Of Expectations, Revises FY22 Outlook
Intuitive Surgical Inc (NASDAQ:ISRG) reported Q1 FY22 adjusted EPS of $1.13, ahead of the consensus of $1.08. It reported revenues…
Humana to Offload Substantial Stake In Kindred At Home Hospice & Personal Care Divisions
Humana Inc (NYSE:HUM) has agreed to divest a majority interest in the Hospice and Personal Care divisions of Humana’s Kindred at…
AbbVie Walks Away From Parkinson’s Drug Pact With BioArctic
AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden’s BioArctic, backing out further development of an experimental Parkinson’s disease drug and…
Read Why Demand For Pfizer’s COVID-19 Antiviral Therapy Is Unexpectedly Low: Reuters
Global demand for Pfizer Inc's (NYSE: PFE) Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a
Pfizer/BioNTech Fourth COVID-19 Vaccine Dose Protects Against Omicron For At Least One Month
A fourth dose of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) provided significant protection against severe disease, hospitalization, and death for at least a month i